Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002284795> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2002284795 endingPage "275" @default.
- W2002284795 startingPage "271" @default.
- W2002284795 abstract "The results of four randomized controlled trials were examined to assess the efficacy of intravenous immunoglobulin (IVIG) for myasthenia gravis (MG) acute exacerbations. The first trial compared plasma exchange (PE) and IVIG in 87 patients. At day 15, the mean change in the Myasthenic Muscular Score (MMS) was 16.6 (95% CI 11.6–21.6) in the PE group and 15.6 (95% CI 10.9–20.3) in the IVIG group (Wilcoxon signed rank test, P = 0.65). The second trial compared IVIG to oral methylprednisolone, and 33 patients were included. The mean (SD) sum of the two most pathological items of the Quantitative Myasthenia Gravis Score (QMGS) at day 0 was 3.9 (1.1) for the IVIG group and 4.2 (0.7) for the methylprednisolone group. At day 14, these values were 2.9 (1.4) for the IVIG group and 2.8 (1.1) for the methylprednisolone group. The third trial compared IVIG 2 g/kg versus placebo for MG worsening. The mean change in QMGS at day 14 was –2.54 in the IVIG group and –0.89 in the placebo group ( P = 0.047). A significant IVIG treatment effect was observed only in patients with more severe disease; the mean difference was −0.10 for mild MG ( P = 0.914) and −3.39 for moderate to severe MG ( P = 0.010). The last trial compared IGIV 2 g/kg versus 1 g/kg for MG acute exacerbation in 173 patients. The mean MMS change in both groups was similar (difference = 3.84; 95% CI −1.03 to 8.71; P = 0.12). In conclusion, IVIG may be used as treatment for MG acute exacerbations. IVIG at a dose of 1 g/kg may be sufficient." @default.
- W2002284795 created "2016-06-24" @default.
- W2002284795 creator A5029354822 @default.
- W2002284795 creator A5052673276 @default.
- W2002284795 date "2008-06-01" @default.
- W2002284795 modified "2023-09-23" @default.
- W2002284795 title "<i>Treatment of Myasthenia Gravis Acute Exacerbations with Intravenous Immunoglobulin</i>" @default.
- W2002284795 cites W1971022805 @default.
- W2002284795 cites W1975133991 @default.
- W2002284795 cites W1979470935 @default.
- W2002284795 cites W2001447887 @default.
- W2002284795 cites W2021441723 @default.
- W2002284795 cites W2048575240 @default.
- W2002284795 cites W2064436710 @default.
- W2002284795 cites W2068001029 @default.
- W2002284795 cites W2109351747 @default.
- W2002284795 cites W2130448030 @default.
- W2002284795 cites W2157547060 @default.
- W2002284795 cites W3021602716 @default.
- W2002284795 cites W4233988018 @default.
- W2002284795 cites W4255171672 @default.
- W2002284795 doi "https://doi.org/10.1196/annals.1405.001" @default.
- W2002284795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18096850" @default.
- W2002284795 hasPublicationYear "2008" @default.
- W2002284795 type Work @default.
- W2002284795 sameAs 2002284795 @default.
- W2002284795 citedByCount "18" @default.
- W2002284795 countsByYear W20022847952012 @default.
- W2002284795 countsByYear W20022847952014 @default.
- W2002284795 countsByYear W20022847952015 @default.
- W2002284795 countsByYear W20022847952016 @default.
- W2002284795 countsByYear W20022847952017 @default.
- W2002284795 countsByYear W20022847952018 @default.
- W2002284795 countsByYear W20022847952021 @default.
- W2002284795 countsByYear W20022847952023 @default.
- W2002284795 crossrefType "journal-article" @default.
- W2002284795 hasAuthorship W2002284795A5029354822 @default.
- W2002284795 hasAuthorship W2002284795A5052673276 @default.
- W2002284795 hasConcept C126322002 @default.
- W2002284795 hasConcept C142724271 @default.
- W2002284795 hasConcept C168563851 @default.
- W2002284795 hasConcept C204787440 @default.
- W2002284795 hasConcept C27081682 @default.
- W2002284795 hasConcept C2776804153 @default.
- W2002284795 hasConcept C2777014857 @default.
- W2002284795 hasConcept C2778105408 @default.
- W2002284795 hasConcept C2780372218 @default.
- W2002284795 hasConcept C42219234 @default.
- W2002284795 hasConcept C535046627 @default.
- W2002284795 hasConcept C71924100 @default.
- W2002284795 hasConcept C90924648 @default.
- W2002284795 hasConceptScore W2002284795C126322002 @default.
- W2002284795 hasConceptScore W2002284795C142724271 @default.
- W2002284795 hasConceptScore W2002284795C168563851 @default.
- W2002284795 hasConceptScore W2002284795C204787440 @default.
- W2002284795 hasConceptScore W2002284795C27081682 @default.
- W2002284795 hasConceptScore W2002284795C2776804153 @default.
- W2002284795 hasConceptScore W2002284795C2777014857 @default.
- W2002284795 hasConceptScore W2002284795C2778105408 @default.
- W2002284795 hasConceptScore W2002284795C2780372218 @default.
- W2002284795 hasConceptScore W2002284795C42219234 @default.
- W2002284795 hasConceptScore W2002284795C535046627 @default.
- W2002284795 hasConceptScore W2002284795C71924100 @default.
- W2002284795 hasConceptScore W2002284795C90924648 @default.
- W2002284795 hasIssue "1" @default.
- W2002284795 hasLocation W20022847951 @default.
- W2002284795 hasLocation W20022847952 @default.
- W2002284795 hasOpenAccess W2002284795 @default.
- W2002284795 hasPrimaryLocation W20022847951 @default.
- W2002284795 hasRelatedWork W1978167968 @default.
- W2002284795 hasRelatedWork W1986536480 @default.
- W2002284795 hasRelatedWork W2018253912 @default.
- W2002284795 hasRelatedWork W2027971573 @default.
- W2002284795 hasRelatedWork W2081459799 @default.
- W2002284795 hasRelatedWork W2125844387 @default.
- W2002284795 hasRelatedWork W2415351211 @default.
- W2002284795 hasRelatedWork W2553539863 @default.
- W2002284795 hasRelatedWork W2886554265 @default.
- W2002284795 hasRelatedWork W3214896713 @default.
- W2002284795 hasVolume "1132" @default.
- W2002284795 isParatext "false" @default.
- W2002284795 isRetracted "false" @default.
- W2002284795 magId "2002284795" @default.
- W2002284795 workType "article" @default.